Sponsor Dossier
Boucher & Muir
Sponsor Dossier for Boucher & Muir. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ARX-METHOTREXATE
- Brand: BUPIVACAINE
- Brand: CLINDAMYCIN
- Brand: DESMOPRESSIN ADVZ
- Brand: EVISTA
- Brand: Ferropods
- Brand: Flecainide
- Brand: FLUTICASONE
- Device (sponsor): Pipette, single channel/multichannel, mechanical
- Device (sponsor): Blood/tissue storage/culture container
- Device (sponsor): Blood donor set, double-pack
- Device (sponsor): Blood donor set, triple-pack
About
Boucher & Muir is an Australian Private Company with ABN 58000140474, registered in New South Wales, with entity status Active. The company operates under the trading name Advanz Pharma (Australia), and has previously traded as Concordia International (Australia) and BNM GROUP.
Portfolio
Boucher & Muir has 36 brands on the ARTG, of which 31 are indexable and 29 carry a Product Information document. 14 brands are PBS-listed, 2 have a PBAC outcome on record, and 0 have an AusPAR on record. Notable brands include ARX-METHOTREXATE, BUPIVACAINE, CLINDAMYCIN, DESMOPRESSIN ADVZ, EVISTA, Ferropods, Flecainide, FLUTICASONE, IONIL, ISAVUCONAZOLE, METHOTREXATE ADVZ, NIMOTOP.
Therapeutic focus
— Pain Management: 5 brands — Cardiology: 5 brands — Infectious Disease: 5 brands — Endocrinology: 4 brands — Neurology: 3 brands — Immunology: 2 brands — Reproductive Health: 2 brands — Other: 2 brands — Psychiatry: 2 brands — Hepatology: 1 brand — Gastroenterology: 1 brand — Respiratory: 1 brand — Oncology: 1 brand — Complementary Medicine: 1 brand — Dermatology: 1 brand
PBS footprint
14 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2017-07-01, across 2 brands with a PBAC outcome on record.